Zusammenfassung
Therapeutisch werden peripher und zentral wirkende Muskelrelaxantien unterschieden. Während peripher wirkende Muskelrelaxantien klinisch vor allem zur Muskelrelaxation bei Narkose eingesetzt werden, kommen zentral wirkende Muskelrelaxantien überwiegend bei der Behandlung krankhafter Tonuserhöhungen der Skelettmuskulatur zur Anwendung.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bundesinstitut für Arzneimittel und Medizinprodukte, Auswertung der Spontanmeldungen zu Tolperison (UAW-Datenbank des BfArM), Schreiben vom 10. Mai 2011.
Cardoso E, Rodrigues B, Lucena R, Oliveira IR, Pedreira G, Melo A (2005): Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a metaanalysis. Arq Neuropsiquiatr 63: 30–33.
Chou R, Peterson K, Helfand M (2004): Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 28: 140–175.
Costa J, Espirito-Santo CC, Borges AA, Ferreira J, Coelho MM, Moore P, Sampaio C (2004): Botulinum toxin type A therapy for blepharospasm. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD004900. DOI: 10.1002/14651858.CD004900.pub2.
Costa J, Espirito-Santo CC, Borges AA, Ferreira J, Coelho MM, Moore P, Sampaio C (2005): Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD003633. DOI: 10.1002/14651858.CD003633.pub2.
Deutsche Gesellschaft für Neurologie (2008): Leitlinie Spastik. http://www.dgn.org/images/stories/dgn/leitlinien/LL2008/ll08kap_096.pdf. Letzter Zugriff 28. April 2011.
Dulin J, Kovacs L, Ramm S, Horvath F, Ebeling L, Kohnen R (1998): Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, ran-domized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 31: 137–142.
Elia AE, Filippini G, Calandrella D, Albanese A (2009): Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 24: 801–812.
European Medicines Agency (2009): Questions and answers on the referral for Myderison tablets containing tolperisone hydrochloride 50 and 150 mg. Internet: www.ema.europa.eu/pdfs/human/referral/myderison/ha_281118q&a.pdf
Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L (2010) Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003469. DOI: 10.1002/14651858.CD003469.pub4.
Infomed (2003): http://www.infomed.org/bad-drug-news/bdn107.html. Letzter Zugriff 11. Mai 2011
Keane RE, Simiand J, Morre M, Biziere K (1988a): Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents. J Pharmacol Exp Ther 245: 692–698.
Keane RE, Bachy A, Morre M, Biziere K (1988b): Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. II. In vitro and in vivo interactions with benzodiazepine binding sites. J Pharmacol Exp Ther 245: 699–705.
Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen F (2001): Botulinumtoxin – Neue Therapieoption für Kinder mit Zerebralparese. Dtsch Ärztebl 98: A3375-A3379.
Quasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W (2008): Tolperisone: A typical representative of a class of centrally acting muscle Relexnants with less sedative side effects. CNS Neurol Therap 14: 107–119.
Shakespeare DT, Boggild M, Young C (2003): Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD001332. DOI: 10.1002/14651858.CD001332.
Simiand J, Keane PE, Biziere K, Soubrie P (1989): Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants. Arch Int Pharmacodyn Ther 297: 272–285.
Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler E, Kropfgans M et al (1993): Thermodynamics of antagonist binding to rat muscarinic M2 receptors: antimuscarinics of the pridinol, sila-pridinol, diphenidol and sila-diphenidol type. Br J Pharmacol 109: 360–370.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Günther, J. (2011). Muskelrelaxantien. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2011. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21992-4_35
Download citation
DOI: https://doi.org/10.1007/978-3-642-21992-4_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-21991-7
Online ISBN: 978-3-642-21992-4
eBook Packages: Medicine (German Language)